What is the appropriate treatment for Streptococcus agalactiae (group B streptococcus) bacteremia?

Treatment of Group B Streptococcus Bacteremia

Penicillin G is the drug of choice for Group B Streptococcus (GBS) bacteremia, administered as high-dose intravenous therapy: 12-18 million units per day divided into 4-6 doses or given continuously for 4 weeks in uncomplicated cases. 1, 2

First-Line Treatment Regimens

For Non-Penicillin Allergic Patients

• Penicillin G: 12-18 million units IV daily in 4-6 divided doses or continuous infusion for 4 weeks 1
• Ampicillin: 2 g IV every 4-6 hours is an acceptable alternative 1
• Ceftriaxone: 2 g IV daily can be used and is particularly convenient for outpatient therapy 1

High doses are specifically recommended because GBS has somewhat higher minimal inhibitory concentrations compared to other streptococci, requiring more aggressive dosing to achieve adequate bactericidal levels 3.

For Penicillin-Allergic Patients

• Vancomycin: 1 g IV every 12 hours for patients with history of anaphylaxis, angioedema, respiratory distress, or urticaria to penicillin 1
• Cefazolin: 2 g IV initial dose, then 1 g IV every 8 hours for patients without high-risk allergy history 1
• Clindamycin: 900 mg IV every 8 hours only if susceptibility testing confirms the isolate is susceptible to both clindamycin and erythromycin 1

Treatment Duration and Considerations

Standard Duration

• 4 weeks of IV therapy for uncomplicated bacteremia 1
• 6 weeks of therapy for prosthetic valve endocarditis 1
• Gentamicin should be added for 2 weeks when treating complicated infections or endocarditis 1

Oral Step-Down Therapy

Recent evidence suggests that oral antibiotic step-down therapy within 5 days may be appropriate for uncomplicated GBS bacteremia after clinical stabilization, with similar clinical failure rates (18.0% vs 24.2%) and significantly shorter hospital stays compared to continued IV therapy 4. However, this approach requires:

• Documented source control 4
• Clinical improvement and hemodynamic stability 4
• Absence of endocarditis or deep-seated infection 4
• No ICU-level care requirements 4

Special Clinical Scenarios

Complicated Infections Requiring Extended Therapy

Group B streptococci produce abscesses and frequently require adjunctive surgery, particularly in cases of:

• Necrotizing fasciitis or soft tissue infections 1, 5
• Osteomyelitis or septic arthritis 2, 3
• Endocarditis (especially prosthetic valve endocarditis with very high mortality) 1

For necrotizing fasciitis, combination therapy with ampicillin-sulbactam plus clindamycin plus ciprofloxacin is recommended for polymicrobial coverage until GBS is confirmed 1.

Neonatal Sepsis

For neonates with suspected GBS sepsis, ampicillin (or benzylpenicillin) combined with gentamicin is the recommended empiric regimen 1. Therapy should include antimicrobial agents active against both GBS and E. coli 1.

Critical Management Principles

Source Control

Surgical intervention is essential for successful treatment of soft-tissue or bone infections, and patients should return to the operating room every 24-36 hours until no further debridement is needed 1.

Risk Factors for Mortality

The following factors are independently associated with 30-day mortality and should prompt more aggressive management:

• Age ≥65 years 2
• High Pitt bacteremia score (≥4) 2
• Absence of fever at presentation 2
• Altered consciousness 2
• Presence of shock 2

Recurrence Prevention

Patients with implantable cardiac devices have 5.8 times higher odds of GBS bacteremia recurrence 6. Additionally, β-lactam allergy increases recurrence risk 3.1-fold, and failure to receive β-lactams or vancomycin as initial empiric treatment significantly increases recurrence 6.

Common Pitfalls to Avoid

• Do not use erythromycin as it is no longer acceptable for GBS treatment due to increasing resistance 1, 7
• Do not use inadequate penicillin dosing—standard doses may be insufficient given GBS's higher MICs 3
• Do not delay surgical consultation for suspected necrotizing infections, as mortality is particularly high in elderly patients with delayed intervention 3, 5
• Ensure susceptibility testing for clindamycin and erythromycin in penicillin-allergic patients, as resistance is increasing and inducible clindamycin resistance may be present even when isolates appear susceptible 1, 7